Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...

Merck said early Monday that a new cholesterol-lowering pill worked well in two late-stage trials, boosting the stock in ...

Enlicitide decanoate demonstrated meaningful LDL lowering in patients with heterozygous familial hypercholesterolemia and ...

Results from the Phase III CORALreef HeFH and CORALreef AddOn studies demonstrated tatistically significant and clinically ...

Merck reports positive results from the first two phase 3 CORALreef trials of enlicitide decanoate to treat adults with hyperlipidemia: Rahway, New Jersey Tuesday, June 10, 2025, ...

Merck & Co., Inc. (NYSE:MRK) on Monday shared topline results from the first two of three Phase 3 clinical trials evaluating ...

Merck (MRK) on Monday announced positive results from the first two of three late-stage clinical trials evaluating the safety ...

Enlicitide decanoate is an investigational oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...